{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:38:43Z","timestamp":1788431923585,"version":"build-2803163510"},"reference-count":132,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment of acromegaly includes surgery followed by chronic medical therapy for persistent growth hormone (GH) excess, and, in some patients, radiation. Treatment is aimed at biochemical normalization, which improves survival and comorbidities. However, many patients experience lifelong burden related to persistent acromegaly manifestations and adverse treatment effects. Long-acting somatostatin receptor ligand (SRL) therapy with octreotide or lanreotide has been the cornerstone of management. Pasireotide long-acting release, a somatostatin receptor multiligand, achieves more favorable biochemical control rates but is associated with an increased risk of hyperglycemia. Pegvisomant, a GH receptor antagonist, can be used as monotherapy or in combination with SRLs. The spectrum of medical therapy has expanded with the advent of oral octreotide capsules; the oral selective somatostatin receptor subtype 2 agonist, paltusotine; and monthly self-administered subcutaneous octreotide. This review outlines the updates to current acromegaly treatment options and their impact on patient outcomes.<\/jats:p>","DOI":"10.1210\/clinem\/dgag152","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:42:19Z","timestamp":1775216539000},"page":"S64-S76","source":"Crossref","is-referenced-by-count":1,"title":["Current treatment landscape of acromegaly"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Frederic","family":"Castinetti","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Aix Marseille University, Marseille Medical Genetics, INSERM U1251 and Assistance Publique Hopitaux de Marseille, La Conception Hospital, French Reference Center for Rare Pituitary Diseases HYPO , Marseille 13005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-9802","authenticated-orcid":false,"given":"Adriana G","family":"Ioachimescu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Molecular Medicine, Department of Medicine and Neurosurgery, Medical College of Wisconsin , Milwaukee, WI 53226 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"11","key":"2026060416134525100_dgag152-B1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026060416134525100_dgag152-B2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10143-025-03797-3","article-title":"Outcome of acromegalic patients undergoing endoscopic endonasal surgery: collaborative French and Italian cohort, a 25-year experience","volume":"48","author":"Baussart","year":"2025","journal-title":"Neurosurg Rev"},{"issue":"2","key":"2026060416134525100_dgag152-B3","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1530\/EJE-19-0124","article-title":"Management of endocrine disease: individualised management of acromegaly","volume":"181","author":"Bollerslev","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416134525100_dgag152-B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026060416134525100_dgag152-B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-024-01487-9","article-title":"Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests","volume":"28","author":"Kinoshita","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026060416134525100_dgag152-B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ando.2019.11.002","article-title":"Fluctuation analysis of postoperative secretory status in patients operated for acromegaly","volume":"81","author":"Graillon","year":"2020","journal-title":"Ann Endocrinol (Paris)"},{"issue":"11","key":"2026060416134525100_dgag152-B7","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","article-title":"Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis","volume":"158","author":"Starnoni","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"2026060416134525100_dgag152-B8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11102-020-01063-x","article-title":"Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review","volume":"23","author":"Agrawal","year":"2020","journal-title":"Pituitary"},{"issue":"11","key":"2026060416134525100_dgag152-B9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","article-title":"Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications","volume":"159","author":"Chen","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"2026060416134525100_dgag152-B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11102-024-01476-y","article-title":"Selective resection of the medial wall of the cavernous sinus in pituitary surgery: results of a prospective single center analysis","volume":"28","author":"Oberman","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"2026060416134525100_dgag152-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11102-025-01635-9","article-title":"Histopathological and radiological predictors of surgical remission failure in GH-secreting pituitary adenomas","volume":"29","author":"Calandrelli","year":"2026","journal-title":"Pituitary"},{"issue":"2","key":"2026060416134525100_dgag152-B12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3171\/2017.2.JNS162673","article-title":"Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature","volume":"129","author":"Almeida","year":"2018","journal-title":"J Neurosurg"},{"issue":"9","key":"2026060416134525100_dgag152-B13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4158\/EP14587.OR","article-title":"Significant elevation of growth hormone level impacts surgical outcomes in acromegaly","volume":"21","author":"Anthony","year":"2015","journal-title":"Endocr Pract"},{"issue":"6","key":"2026060416134525100_dgag152-B14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: a Dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416134525100_dgag152-B15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11102-024-01432-w","article-title":"Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis","volume":"27","author":"Del Corso","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026060416134525100_dgag152-B16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/s-0043-57233","article-title":"Predictors of remission of acromegaly following surgical treatment in growth hormone-secreting pituitary adenoma","volume":"85","author":"Konar","year":"2024","journal-title":"J Neurol Surg B Skull Base"},{"key":"2026060416134525100_dgag152-B17","doi-asserted-by":"crossref","first-page":"743052","DOI":"10.3389\/fendo.2021.743052","article-title":"Postoperative GH and degree of reduction in IGF-1 predicts postoperative hormonal remission in acromegaly","volume":"12","author":"Cardinal","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026060416134525100_dgag152-B18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3171\/jns.1998.89.3.0353","article-title":"Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly","volume":"89","author":"Freda","year":"1998","journal-title":"J Neurosurg"},{"issue":"3","key":"2026060416134525100_dgag152-B19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3171\/2021.11.JNS212137","article-title":"Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients","volume":"137","author":"Guo","year":"2022","journal-title":"J Neurosurg"},{"issue":"9","key":"2026060416134525100_dgag152-B20","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060416134525100_dgag152-B21","doi-asserted-by":"crossref","first-page":"e13434","DOI":"10.1111\/jne.13434","article-title":"Early postoperative growth hormone measurement as a predictive marker for acromegaly remission","volume":"36","author":"Kraljevic","year":"2024","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"2026060416134525100_dgag152-B22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3171\/jns.2003.98.4.0719","article-title":"Assessment of long-term remission of acromegaly following surgery","volume":"98","author":"Krieger","year":"2003","journal-title":"J Neurosurg"},{"key":"2026060416134525100_dgag152-B23","doi-asserted-by":"crossref","first-page":"1571598","DOI":"10.3389\/fendo.2025.1571598","article-title":"Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly","volume":"16","author":"Chong","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026060416134525100_dgag152-B24","doi-asserted-by":"crossref","first-page":"e2178","DOI":"10.1210\/clinem\/dgae126","article-title":"Differences between GH- and PRL-cosecreting and GH-secreting pituitary adenomas: a series of 604 cases","volume":"109","author":"Araujo-Castro","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026060416134525100_dgag152-B25","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s40618-024-02321-6","article-title":"Recurrence in acromegaly: two tertiary centers experience and review of the literature","volume":"47","author":"Cremaschi","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026060416134525100_dgag152-B26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2026060416134525100_dgag152-B27","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","volume":"46","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"issue":"9","key":"2026060416134525100_dgag152-B28","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2026060416134525100_dgag152-B29","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide autogel-120 mg treatment given first-line in acromegaly","volume":"71","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060416134525100_dgag152-B30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"issue":"10","key":"2026060416134525100_dgag152-B31","doi-asserted-by":"crossref","first-page":"bvad104","DOI":"10.1210\/jendso\/bvad104","article-title":"Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis","volume":"7","author":"Fleseriu","year":"2023","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026060416134525100_dgag152-B32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-024-01479-9","article-title":"IGF-I levels during standard lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly","volume":"28","author":"Chiloiro","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026060416134525100_dgag152-B33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11102-022-01285-1","article-title":"A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly","volume":"26","author":"Fleseriu","year":"2023","journal-title":"Pituitary"},{"issue":"9","key":"2026060416134525100_dgag152-B34","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060416134525100_dgag152-B35","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly\u2014a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416134525100_dgag152-B36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1210\/clinem\/dgad673","article-title":"The multibiomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort","volume":"109","author":"Chiloiro","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060416134525100_dgag152-B37","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416134525100_dgag152-B38","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"2026060416134525100_dgag152-B39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1210\/clinem\/dgaf375","article-title":"Integrative machine learning approach for predicting resistance to first-generation receptor ligands in acromegaly","volume":"111","author":"Lin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416134525100_dgag152-B40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/clinem\/dgae444","article-title":"Personalized medicine in acromegaly: the ACROFAST study","volume":"110","author":"Marques-Pamies","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416134525100_dgag152-B41","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416134525100_dgag152-B42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/cen.14748","article-title":"Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month","volume":"97","author":"Benderradji","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026060416134525100_dgag152-B43","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size","volume":"87","author":"Bevan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026060416134525100_dgag152-B44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/ERC-19-0327","article-title":"Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness","volume":"26","author":"Marques","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026060416134525100_dgag152-B45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11154-022-09782-1","article-title":"The immune microenviroment in somatotropinomas: from biology to personalized and target therapy","volume":"24","author":"Chiloiro","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"2026060416134525100_dgag152-B46","doi-asserted-by":"crossref","first-page":"bvac114","DOI":"10.1210\/jendso\/bvac114","article-title":"Preoperative medical treatment for patients with acromegaly: yes or no?","volume":"6","author":"Albarel","year":"2022","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026060416134525100_dgag152-B47","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1038\/s41598-019-50639-6","article-title":"Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"2026060416134525100_dgag152-B48","doi-asserted-by":"crossref","first-page":"178053","DOI":"10.1016\/j.ejphar.2025.178053","article-title":"Real-world drug safety study of somatostatin analogs based on the food and drug administration adverse event reporting system database","volume":"1005","author":"Ye","year":"2025","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2026060416134525100_dgag152-B49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"2026060416134525100_dgag152-B50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416134525100_dgag152-B51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12020-022-03227-0","article-title":"Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review","volume":"79","author":"Boguszewski","year":"2023","journal-title":"Endocrine"},{"issue":"2","key":"2026060416134525100_dgag152-B52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12020-020-02529-5","article-title":"Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel","volume":"71","author":"Akirov","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"2026060416134525100_dgag152-B53","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12325-020-01600-x","article-title":"Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review","volume":"38","author":"Cella","year":"2021","journal-title":"Adv Ther"},{"key":"2026060416134525100_dgag152-B54","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026060416134525100_dgag152-B55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ejendo\/lvaf200","article-title":"Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection","volume":"193","author":"Remba-Shapiro","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026060416134525100_dgag152-B56","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/17425247.2021.1942838","article-title":"Transient permeation enhancer\u00ae (TPE\u00ae) technology for oral delivery of octreotide: a technological evaluation","volume":"18","author":"Brayden","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"2026060416134525100_dgag152-B57","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11102-021-01163-2","article-title":"Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results","volume":"24","author":"Labadzhyan","year":"2021","journal-title":"Pituitary"},{"issue":"10","key":"2026060416134525100_dgag152-B58","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416134525100_dgag152-B59","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-22-0220","article-title":"Durable biochemical response and safety with oral octreotide capsules in acromegaly","volume":"187","author":"Samson","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060416134525100_dgag152-B60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026060416134525100_dgag152-B61","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1210\/clinem\/dgad365","article-title":"MPOWERED trial open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly","volume":"108","author":"Fleseriu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060416134525100_dgag152-B62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17446651.2024.2363540","article-title":"Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use","volume":"19","author":"Fleseriu","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"2026060416134525100_dgag152-B63","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"2026060416134525100_dgag152-B64","doi-asserted-by":"crossref","first-page":"A863","DOI":"10.1210\/jendso\/bvaf149.1636","article-title":"SUN-051 CAM2029, an octreotide subcutaneous depot, provides long-term and sustained biochemical control of acromegaly: final analysis of the core part of the ACROINNOVA 2 phase 3 trial","volume":"9","author":"Spencer-Segal","year":"2025","journal-title":"J Endocr Soc"},{"issue":"2","key":"2026060416134525100_dgag152-B65","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"2026060416134525100_dgag152-B66","doi-asserted-by":"crossref","first-page":"101710","DOI":"10.1016\/j.ando.2025.101710","article-title":"New treatments for acromegaly: is a revolution underway?","volume":"86","author":"Cristante","year":"2025","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2026060416134525100_dgag152-B67","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl_1","key":"2026060416134525100_dgag152-B68","first-page":"A625","article-title":"12535 efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled PATHFNDR-2 study","volume":"8","author":"Biller","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026060416134525100_dgag152-B69","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1210\/clinem\/dgae489","article-title":"Paltusotine: a step toward precision medicine in acromegaly","volume":"110","author":"Castinetti","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416134525100_dgag152-B70","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060416134525100_dgag152-B71","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026060416134525100_dgag152-B72","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060416134525100_dgag152-B73","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060416134525100_dgag152-B74","doi-asserted-by":"crossref","first-page":"935759","DOI":"10.3389\/fendo.2022.935759","article-title":"Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis","volume":"13","author":"Mondin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026060416134525100_dgag152-B75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","article-title":"Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis","volume":"26","author":"Biagetti","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"2026060416134525100_dgag152-B76","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s40618-023-02299-7","article-title":"Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center","volume":"47","author":"Pirchio","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026060416134525100_dgag152-B77","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026060416134525100_dgag152-B78","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"key":"2026060416134525100_dgag152-B79","doi-asserted-by":"crossref","first-page":"1348990","DOI":"10.3389\/fendo.2024.1348990","article-title":"Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement","volume":"15","author":"St\u00f6rmann","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026060416134525100_dgag152-B80","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2026060416134525100_dgag152-B81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"6","key":"2026060416134525100_dgag152-B82","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ando.2023.08.003","article-title":"Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP)","volume":"84","author":"Brue","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"2026060416134525100_dgag152-B83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/EJE-17-0996","article-title":"Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant","volume":"178","author":"Strasburger","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"2026060416134525100_dgag152-B84","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"9295","key":"2026060416134525100_dgag152-B85","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"2026060416134525100_dgag152-B86","doi-asserted-by":"crossref","first-page":"e230247","DOI":"10.1530\/EC-23-0247","article-title":"Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis","volume":"13","author":"Giampietro","year":"2024","journal-title":"Endocr Connect"},{"issue":"4","key":"2026060416134525100_dgag152-B87","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1530\/EJE-16-0956","article-title":"A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues","volume":"176","author":"Franck","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416134525100_dgag152-B88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","article-title":"Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant","volume":"92","author":"Parkinson","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416134525100_dgag152-B89","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","article-title":"Predictors and rates of treatment-resistant tumor growth in acromegaly","volume":"153","author":"Besser","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060416134525100_dgag152-B90","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/EJE-08-0205","article-title":"Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials","volume":"159","author":"Jimenez","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060416134525100_dgag152-B91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","article-title":"Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies","volume":"63","author":"Leonart","year":"2019","journal-title":"Endocrine"},{"issue":"6","key":"2026060416134525100_dgag152-B92","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in acrostudy","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416134525100_dgag152-B93","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"2026060416134525100_dgag152-B94","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects","volume":"30","author":"Moller","year":"2009","journal-title":"Endocr Rev"},{"issue":"2","key":"2026060416134525100_dgag152-B95","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/ijms26020465","article-title":"Differential impact of medical therapies for acromegaly on glucose metabolism","volume":"26","author":"Gatto","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026060416134525100_dgag152-B96","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416134525100_dgag152-B97","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","article-title":"Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience","volume":"25","author":"Salvatori","year":"2022","journal-title":"Pituitary"},{"issue":"1","key":"2026060416134525100_dgag152-B98","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/cen.14309","article-title":"Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly","volume":"94","author":"Dichtel","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026060416134525100_dgag152-B99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11102-010-0289-5","article-title":"Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients","volume":"14","author":"Neggers","year":"2011","journal-title":"Pituitary"},{"issue":"5","key":"2026060416134525100_dgag152-B100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/EJE-15-1150","article-title":"What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?","volume":"174","author":"Muhammad","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060416134525100_dgag152-B101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","article-title":"Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study","volume":"22","author":"Camara","year":"2019","journal-title":"Pituitary"},{"issue":"9471","key":"2026060416134525100_dgag152-B102","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"2026060416134525100_dgag152-B103","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026060416134525100_dgag152-B104","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416134525100_dgag152-B105","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12902-020-0545-2","article-title":"Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"10","key":"2026060416134525100_dgag152-B106","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jc.2005-0531","article-title":"Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist","volume":"90","author":"J\u00f8rgensen","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416134525100_dgag152-B107","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1210\/jcem.86.2.7206","article-title":"Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient","volume":"86","author":"van der Lely","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026060416134525100_dgag152-B108","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026060416134525100_dgag152-B109","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060416134525100_dgag152-B110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-007-0037-7","article-title":"Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA","volume":"10","author":"De Marinis","year":"2007","journal-title":"Pituitary"},{"issue":"9","key":"2026060416134525100_dgag152-B111","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060416134525100_dgag152-B112","doi-asserted-by":"crossref","first-page":"646","DOI":"10.20945\/2359-3997000000195","article-title":"The position of combined medical treatment in acromegaly","volume":"63","author":"Coopmans","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"11","key":"2026060416134525100_dgag152-B113","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1210\/jc.2019-00825","article-title":"Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study","volume":"104","author":"Chiloiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060416134525100_dgag152-B114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060416134525100_dgag152-B115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ecl.2020.05.006","article-title":"The role of dopamine agonists in pituitary adenomas","volume":"49","author":"Giraldi","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"2026060416134525100_dgag152-B116","doi-asserted-by":"crossref","first-page":"101887","DOI":"10.1016\/j.beem.2024.101887","article-title":"Real-world value of cabergoline in the treatment of acromegaly","volume":"38","author":"Shimon","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2026060416134525100_dgag152-B117","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060416134525100_dgag152-B118","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060416134525100_dgag152-B119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"key":"2026060416134525100_dgag152-B120","first-page":"PEP8.3","article-title":"Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy","volume":"73","author":"Fleseriu","year":"2021","journal-title":"Endocr Abs"},{"issue":"3","key":"2026060416134525100_dgag152-B121","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-024-01387-y","article-title":"Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades","volume":"27","author":"Amodru","year":"2024","journal-title":"Pituitary"},{"issue":"5","key":"2026060416134525100_dgag152-B122","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060416134525100_dgag152-B123","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrendo.2010.4","article-title":"Role of stereotactic radiosurgery in the management of pituitary adenomas","volume":"6","author":"Castinetti","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2026060416134525100_dgag152-B124","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11060-020-03552-2","article-title":"Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes","volume":"148","author":"Singh","year":"2020","journal-title":"J Neurooncol"},{"issue":"3","key":"2026060416134525100_dgag152-B125","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/neuros\/nyy178","article-title":"Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study","volume":"84","author":"Ding","year":"2019","journal-title":"Neurosurgery"},{"issue":"4","key":"2026060416134525100_dgag152-B126","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3171\/2018.5.JNS18509","article-title":"Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: a multicenter, international study","volume":"131","author":"Cordeiro","year":"2019","journal-title":"J Neurosurg"},{"issue":"8","key":"2026060416134525100_dgag152-B127","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-8587(22)00160-7","article-title":"Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance","volume":"10","author":"Hamblin","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026060416134525100_dgag152-B128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/EJE-21-0826","article-title":"Lack of delayed neurocognitive side effects of gamma knife radiosurgery in acromegaly: the later-ac study","volume":"186","author":"Castinetti","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2026060416134525100_dgag152-B129","first-page":"i58","article-title":"Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors","volume":"7","author":"Mantziaris","year":"2025","journal-title":"Neurooncol Adv"},{"issue":"2","key":"2026060416134525100_dgag152-B130","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12020-019-01955-4","article-title":"Efficacy and safety of fractionated conformal radiation therapy in acromegaly: a long-term follow-up study","volume":"65","author":"Gonzales-Virla","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"2026060416134525100_dgag152-B131","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4158\/EP.13.7.726","article-title":"Proton stereotactic radiosurgery in management of persistent acromegaly","volume":"13","author":"Petit","year":"2007","journal-title":"Endocr Pract"},{"issue":"3","key":"2026060416134525100_dgag152-B132","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijrobp.2014.06.068","article-title":"Outcomes of proton therapy for patients with functional pituitary adenomas","volume":"90","author":"Wattson","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag152\/67993766\/dgag152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S64\/67993766\/dgag152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S64\/67993766\/dgag152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:14:08Z","timestamp":1780604048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S64\/8644428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":132,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag152","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,8]]}}}